Biocon Consortium Wins 10-Year Exclusive Pertuzumab Supply Contract in Brazil
Biocon Ltd 路 Press Release 路 08 Sept 2026, 2:01 pm
Biocon Consortium Wins 10-Year Exclusive Pertuzumab Supply Contract in Brazil Biocon Limited announced on 8th Sep'26 that its consortium with Bahiafarma and Bionovis secured a 100% allocation under Brazil's 10-year Productive Development Partnership (PDP) program for Pertuzumab, a HER2-positive breast cancer therapy. The partnership grants exclusive access to Brazil鈥檚 public healthcare system, representing ~70% of the nation's demand for the drug. Biocon will receive milestone payments and revenue share over the 10-year period, with the product undergoing phased local manufacturing in Brazil over the mid-to-long term.
Original exchange filing (PDF)
More announcements from Biocon Ltd
- Press Release 路 18 Nov 2026
- Press Release 路 16 Nov 2026
- Intimation on Schedule of Meetings with Analyst(s)/institutional Investor(s) 路 12 Nov 2026
- Earnings Call Transcript for Q2 FY27 路 12 Nov 2026
- Audio and Video Recording of Q2 FY27 Earnings Call 路 05 Nov 2026
- Communication regarding withholding of final dividend for the FY 2025-26 路 04 Nov 2026
- Investor Presentation 路 04 Nov 2026
- Change in Senior Management Personnel 路 04 Nov 2026
